{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T11:52:40Z","timestamp":1723290760630},"reference-count":48,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1136\/bmjgast-2018-000209","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T14:45:18Z","timestamp":1534776318000},"page":"e000209","update-policy":"http:\/\/dx.doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Systematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia"],"prefix":"10.1136","volume":"5","author":[{"given":"Bin","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanpu","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yee Hui","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher D","family":"Stave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangsuo","family":"Dang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zongfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiro","family":"Furusyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramsey C","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mindie H","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,8,20]]},"reference":[{"key":"2018082007451177000_5.1.e000209.1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Polaris Observatory HCV Collaborators","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2018082007451177000_5.1.e000209.2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i34.7824"},{"key":"2018082007451177000_5.1.e000209.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2011.01441.x"},{"key":"2018082007451177000_5.1.e000209.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"2018082007451177000_5.1.e000209.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316145"},{"key":"2018082007451177000_5.1.e000209.6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.07.043"},{"key":"2018082007451177000_5.1.e000209.7","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27726"},{"key":"2018082007451177000_5.1.e000209.8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/cld.442","article-title":"New treatments for HCV: perspective from Asia","volume":"5","author":"Yu","year":"2015","journal-title":"Clin Liver Dis"},{"key":"2018082007451177000_5.1.e000209.9","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/jgh.13628","article-title":"Results of sofosbuvir-based combination therapy for chronic hepatitis C cohort of Indian patients in real-life clinical practice","volume":"32","author":"Sood","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"2018082007451177000_5.1.e000209.10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jceh.2016.07.001","article-title":"Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016","volume":"6","author":"Puri","year":"2016","journal-title":"J Clin Exp Hepatol"},{"issue":"Suppl 1","key":"2018082007451177000_5.1.e000209.11","first-page":"S839","article-title":"Diagnosis, Management And Prevention Of Hepatitis C In Pakistan 2017","volume":"28","author":"Umar","year":"2016","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"2018082007451177000_5.1.e000209.12","doi-asserted-by":"crossref","unstructured":"Capileno YA , Van den Bergh R , Donchunk D , et al . Management of chronic Hepatitis C at a primary health clinic in the high-burden context of Karachi, Pakistan. PLoS One 2017;12:e0175562.doi:10.1371\/journal.pone.0175562","DOI":"10.1371\/journal.pone.0175562"},{"key":"2018082007451177000_5.1.e000209.13","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12072-016-9717-6","article-title":"APASL consensus statements and recommendation on treatment of hepatitis C","volume":"10","author":"Omata","year":"2016","journal-title":"Hepatol Int"},{"key":"2018082007451177000_5.1.e000209.14","unstructured":"Asia. In: MeSH Unique ID: D001208: MeSH."},{"key":"2018082007451177000_5.1.e000209.15"},{"key":"2018082007451177000_5.1.e000209.16","doi-asserted-by":"publisher","DOI":"10.1186\/2049-3258-72-39"},{"key":"2018082007451177000_5.1.e000209.17","doi-asserted-by":"crossref","unstructured":"Michael Borenstein LVH , Higgins JPT , Rothstein HR . Chapter 20: Meta-Regression. Introduction to Meta-Analysis: John Wiley & Sons, Ltd, 2009:202.","DOI":"10.1002\/9780470743386"},{"key":"2018082007451177000_5.1.e000209.18","doi-asserted-by":"crossref","unstructured":"Higgins JP , Thompson SG , Deeks JJ , et al . Measuring inconsistency in meta-analyses. BMJ (Clinical research ed . 2003;327:557\u201360.","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2018082007451177000_5.1.e000209.19","doi-asserted-by":"publisher","DOI":"10.2307\/2533446"},{"key":"2018082007451177000_5.1.e000209.20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7119.1371"},{"key":"2018082007451177000_5.1.e000209.21","unstructured":"R Core Team. R: A language and environment for statistical computing. 3.4.1 edn: R Foundation for Statistical Computing, 2017."},{"key":"2018082007451177000_5.1.e000209.22","doi-asserted-by":"crossref","unstructured":"Schwarzer G . meta: An R package for meta-analysis. In: R news 2007.","DOI":"10.32614\/CRAN.package.meta"},{"key":"2018082007451177000_5.1.e000209.23","unstructured":"Hadley W . ggplot2: Elegant graphics for data analysis. New York: Springer-Verlag, 2009."},{"key":"2018082007451177000_5.1.e000209.24","unstructured":"Wells GA SB , O\u2019Connell D , Peterson J , et al . The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"2018082007451177000_5.1.e000209.25","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-3-54"},{"key":"2018082007451177000_5.1.e000209.26","first-page":"S1091","article-title":"Sofosbuvir and ribavirin without or with pegylated interferon for hepatitis C genotype 3: A real world experience","volume":"11","author":"Abbas","year":"2017","journal-title":"Hepatol Int"},{"key":"2018082007451177000_5.1.e000209.27","first-page":"S884","article-title":"Sofosbuvir for the treatment of hepatitis C genotype 3 infected patients In Pakistan","volume":"28","author":"Akhter","year":"2016","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"2018082007451177000_5.1.e000209.28","first-page":"962A","article-title":"Multi-center experience using Sofosbuvir & ribavirin with and without pegylated interferon to treat hepatitis C patients with and without liver cirrhosis (RESiP study: Real-life experience with sofosbuvir in Pakistan)","volume":"63","author":"Farooqi","year":"2016","journal-title":"Hepatology"},{"key":"2018082007451177000_5.1.e000209.29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12664-017-0763-3","article-title":"Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience","volume":"36","author":"Goel","year":"2017","journal-title":"Indian J Gastroenterol"},{"key":"2018082007451177000_5.1.e000209.30","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/jvh.12721","article-title":"Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience","volume":"24","author":"Hlaing","year":"2017","journal-title":"J Viral Hepat"},{"key":"2018082007451177000_5.1.e000209.31","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s12664-016-0713-5","article-title":"Efficacy and safety of sofosbuvir-based therapy for chronic hepatitis C infection in \"real-life\" cohort","volume":"35","author":"Mehta","year":"2016","journal-title":"Indian J Gastroenterol"},{"key":"2018082007451177000_5.1.e000209.32","first-page":"1","article-title":"The efficacy of 12weeks of sofosbuvir, daclatasvir, and ribavirin in treating hepatitis C patients with cirrhosis, genotypes 1 and 3","volume":"17","author":"Merat","year":"2017","journal-title":"Hepat mon"},{"key":"2018082007451177000_5.1.e000209.33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.12669\/pjms.331.12163","article-title":"Sofosbuvir based therapy in hepatitis C patients with and without cirrhosis: Is there difference?","volume":"33","author":"Sarwar","year":"2017","journal-title":"Pak J Med Sci"},{"key":"2018082007451177000_5.1.e000209.34","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/jgh.13595","article-title":"Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C","volume":"32","author":"Satsangi","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"2018082007451177000_5.1.e000209.35","first-page":"S15","article-title":"Sofosbuvir plus ribavirin in the treatment of chronic HCV infection in India","volume":"10","author":"Shah","year":"2016","journal-title":"Hepatol Int"},{"key":"2018082007451177000_5.1.e000209.36","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s12072-017-9794-1","article-title":"Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study","volume":"11","author":"Sidhu","year":"2017","journal-title":"Hepatol Int"},{"key":"2018082007451177000_5.1.e000209.37","first-page":"S132","article-title":"Treatment chronic hepatitis C Myanmar patients with sofosbuvir, pegylated interferon and ribavirin","volume":"10","author":"Win","year":"2016","journal-title":"Hepatol Int"},{"key":"2018082007451177000_5.1.e000209.38","first-page":"S27","article-title":"Dramatic response of hepatitis C patients chronically infected with HCV\u00a0genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan","volume":"11","author":"Yousuf","year":"2017","journal-title":"Hepatol int"},{"key":"2018082007451177000_5.1.e000209.39","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26905"},{"key":"2018082007451177000_5.1.e000209.40","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cgh.2016.10.034","article-title":"Identification of the best direct-acting antiviral regimen for\u00a0patients with hepatitis C virus genotype 3 infection: a\u00a0systematic review and network meta-analysis","volume":"15","author":"Berden","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2018082007451177000_5.1.e000209.41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214854"},{"key":"2018082007451177000_5.1.e000209.42","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70033-1"},{"key":"2018082007451177000_5.1.e000209.43","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12279"},{"key":"2018082007451177000_5.1.e000209.44","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/apt.14592","article-title":"High efficacy of sofosbuvir\/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection","volume":"47","author":"von Felden","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"2018082007451177000_5.1.e000209.45","first-page":"S890","article-title":"Role of generics in treatment of hepatitis c infection","volume":"28","author":"Umar","year":"2016","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"2018082007451177000_5.1.e000209.46","doi-asserted-by":"crossref","unstructured":"Younossi ZM , Stepanova M , Chan HL , et al . Patient-reported outcomes in Asian patients with chronic hepatitis C treated with ledipasvir and sofosbuvir. Medicine 2016;95:e2702.doi:10.1097\/MD.0000000000002702","DOI":"10.1097\/MD.0000000000002702"},{"key":"2018082007451177000_5.1.e000209.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2014.09.025"},{"key":"2018082007451177000_5.1.e000209.48","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13269"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2018-000209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T11:28:54Z","timestamp":1720524534000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2018-000209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,8,20]]},"published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1136\/bmjgast-2018-000209"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2018-000209","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}